Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.

Chang Xu Kie Kyon HuangJia Hao LawJoy Shijia ChuaTaotao ShengNatasha M FloresMelissa Pool PizziAtsushi OkabeAngie Lay Keng TanFeng ZhuVikrant KumarXiaoyin LuAna Morales BenitezBenedict Shi Xiang LianHaoran MaShamaine Wei Ting HoKalpana RamnarayananChukwuemeka George Anene-NzeluMilad Razavi-MohseniSiti Aishah Binte Abdul GhaniSu Ting TayXuewen OngMing Hui LeeYu Amanda GuoHassan AshktorabDuane SmootShang LiAnders Jacobsen SkanderupMichael A BeerRoger Sik Yin FooJoel Shi Hao WongKaushal SanghviWei Peng YongRaghav Sundar Atsushi KanedaShyam PrabhakarPawel Karol MazurJaffer A AjaniKhay-Guan YeohJimmy Bok-Yan SoPatrick Boon-Ooi Tannull null

Published in: Gut (2023)

-mutated GCs targeting both tumour-intrinsic (BRD4-assocatiated promoter activation) and extrinsic (NFKB immunomodulation) cancer phenotypes.

Keyphrases

papillary thyroid
dna methylation
squamous cell
gene expression
high throughput
transcription factor
wild type
cancer therapy
lymph node metastasis
young adults